Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100295

1.

Gleason 5 + 3 = 8 Prostate Cancer: Much More like Gleason 9?

Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL.

BJU Int. 2015 Jul 24. doi: 10.1111/bju.13239. [Epub ahead of print]

PMID:
26207642
2.

Can Confirmatory Biopsy be Omitted in Prostate Cancer Active Surveillance Patients with Favorable Diagnostic Features?

Satasivam P, Poon BY, Ehdaie B, Vickers AJ, Eastham JA.

J Urol. 2015 Jul 17. pii: S0022-5347(15)04410-9. doi: 10.1016/j.juro.2015.07.078. [Epub ahead of print]

PMID:
26192258
3.

Assessment of Prospectively Assigned Likert Scores for Targeted MR Imaging-Transrectal US Fusion Biopsies in Patients with Suspected Prostate Cancer.

Costa DN, Lotan Y, Rofsky NM, Roehrborn C, Liu A, Hornberger B, Xi Y, Francis F, Pedrosa I.

J Urol. 2015 Jul 17. pii: S0022-5347(15)04412-2. doi: 10.1016/j.juro.2015.07.080. [Epub ahead of print]

PMID:
26192254
4.

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgo A, Brown L, Tree A, Miralbell R, De Meerleer G.

Eur Urol. 2015 Jul 16. pii: S0302-2838(15)00608-9. doi: 10.1016/j.eururo.2015.07.004. [Epub ahead of print]

PMID:
26189689
5.

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, Heller G, Carver B, Rosen N, Scher HI.

Cancer. 2015 Jul 15. doi: 10.1002/cncr.29578. [Epub ahead of print]

PMID:
26178426
6.

Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.

Habashy D, Losco G, Tse V, Collins R, Chan L.

BJU Int. 2015 Jul 14. doi: 10.1111/bju.13110. [Epub ahead of print]

PMID:
26176660
7.

Expression levels of heat shock protein 27 and cellular FLICE-like inhibitory protein in prostate cancer correlate with Gleason score sum and pathologic stage.

Lee SW, Cho JM, Cho HJ, Kang JY, Kim EK, Yoo TK.

Korean J Urol. 2015 Jul;56(7):505-14. doi: 10.4111/kju.2015.56.7.505. Epub 2015 Jul 7.

8.

Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.

Yoo S, Kim JK, Jeong IG.

Korean J Urol. 2015 Jul;56(7):487-97. doi: 10.4111/kju.2015.56.7.487. Epub 2015 Jun 30. Review.

9.

10-year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate Specific Antigen Screening Era.

Mendhiratta N, Lee T, Prabhu V, Llukani E, Lepor H.

Urology. 2015 Jul 8. pii: S0090-4295(15)00635-4. doi: 10.1016/j.urology.2015.05.034. [Epub ahead of print]

PMID:
26163812
10.

Efficacy and Safety of Abiraterone Acetate in Elderly (≥75 Years) Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer.

Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ.

J Urol. 2015 Jul 4. pii: S0022-5347(15)04316-5. doi: 10.1016/j.juro.2015.07.004. [Epub ahead of print]

PMID:
26151676
11.

Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

Cooperberg MR, Carroll PR.

JAMA. 2015 Jul 7;314(1):80-2. doi: 10.1001/jama.2015.6036. No abstract available.

PMID:
26151271
12.

Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.

Bokhorst LP, Alberts AR, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Bangma CH, Roobol MJ; PRIAS study group.

Eur Urol. 2015 Jun 29. pii: S0302-2838(15)00515-1. doi: 10.1016/j.eururo.2015.06.012. [Epub ahead of print]

PMID:
26138043
13.

Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.

Kim EA, Kim YH, Kang HW, Yoon HY, Kim WT, Kim YJ, Yun SJ, Moon SK, Choi YH, Kim IY, Lee SC, Kim WJ.

J Korean Med Sci. 2015 Jul;30(7):937-42. doi: 10.3346/jkms.2015.30.7.937. Epub 2015 Jun 10.

14.

Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols.

Kang HW, Lee JY, Kwon JK, Jeh SU, Jung HD, Cho KS, Ham WS, Choi YD.

J Korean Med Sci. 2015 Jul;30(7):932-6. doi: 10.3346/jkms.2015.30.7.932. Epub 2015 Jun 10.

15.

Male Urinary Incontinence: Associated Risk Factors and Electromyography Biofeedback Results in Quality of Life.

Fernández-Cuadros ME, Nieto-Blasco J, Geanini-Yagüez A, Ciprián-Nieto D, Padilla-Fernández B, Lorenzo-Gómez MF.

Am J Mens Health. 2015 Jun 30. pii: 1557988315590653. [Epub ahead of print]

PMID:
26130728
16.

[Recommended duration of androgen suppression of localized pancreatic cancer before radiotherapy is still uncertain].

Goldner G.

Strahlenther Onkol. 2015 May;191(5):458-9. doi: 10.1007/s00066-015-0820-8. German. No abstract available.

PMID:
26120653
17.

Age is associated with upgrading at confirmatory biopsy among men with prostate cancer treated with active surveillance.

Anderson CB, Sternberg IA, Karen-Paz G, Kim PH, Sjoberg D, Vargas HA, Touijer K, Eastham JA, Ehdaie B.

J Urol. 2015 Jun 25. pii: S0022-5347(15)04295-0. doi: 10.1016/j.juro.2015.06.084. [Epub ahead of print]

PMID:
26119671
18.

Pseudohyperplastic prostate carcinoma: histologic patterns and differential diagnosis.

Arista-Nasr J, Martínez-Benítez B, Aguilar-Ayala EL, Aleman-Sanchez CN, Bornstein-Quevedo L, Albores-Saavedra J.

Ann Diagn Pathol. 2015 Aug;19(4):253-60. doi: 10.1016/j.anndiagpath.2015.04.009. Epub 2015 May 22.

PMID:
26101154
19.

Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.

Nguyen-Nielsen M, Liede A, Maegbaek ML, Borre M, Harving N, Hernandez RK, Sørensen HT, Ehrenstein V.

Cancer Epidemiol. 2015 Jun 19. pii: S1877-7821(15)00126-5. doi: 10.1016/j.canep.2015.05.008. [Epub ahead of print]

PMID:
26100365
20.

[VALUE OF THE -2PROPSA INDEX AND THE PROSTATE HEALTH INDEX IN PATIENTS WITH PROSTATE CANCER: REVIEW OF LITERATURE AND DATA OF RUSSIAN PROSPECTIVE STUDY].

Kolontarev KB, Govorov AV, Osipova TA, Sidorenkov AV, Pushkar DY.

Urologiia. 2015 Jan-Feb;(1):49-53. Review. Russian.

PMID:
26094387
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk